Bill
HRES 803
Urging the Director of the Food and Drug Administration to reevaluate the safety of all chemical abortion drugs in light of recent independent studies, and for other purposes.
119th Congress
Introduced by Robert Aderholt and 11 co-sponsors
HRES 803 urges the FDA to reassess the safety of chemical abortion drugs, impacting patients and healthcare providers by ensuring transparency and updated safety information.
Submitted in House